Safety Study of Vx006 Vaccine in Solid Tumor Patients
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
Patients with histologically proven malignancy with documented disease control (objective
response or stable disease) or Not Evaluable Disease (NED) expectancy > 6 months; only
HLA-A*02 positive patients.
The primary objective of the trial is to compare safety and tolerability of four different
doses of Vx-006. The secondary objective is to compare immunogenicity of four different doses
of the Vx-006.